Sickle Cell Anemia Testing & Screening Market (By Technology: High-performance Liquid Chromatography, Hemoglobin Electrophoresis, Isoelectric focusing, Paper-Based Rapid Diagnostics, Lateral Flow Immunoassay, Point-of-Care Tests, Others); By Age: Adult Screening (25 to 60 years), Newborn Screening (12 months and below), Other Age Groups (1 to 25 & above 60 years); By Sector: Private Labs, Government Labs, Corporate Labs, PPP) - Global Industry Analysis, Market Size, Opportunities and Forecast 2021 - 2028

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 190

The global sickle cell anemia testing & screening market is anticipated to grow at a CAGR of around 6.2% during the forecast period 2021 to 2028 and to reach around US$ 337.9 Mn by 2028.

Market Dynamics

The total amount of hemoglobin S in a blood sample or mutations in the hemoglobin genes is measured by sickle cell. WHO estimates that more than 300,000 babies are born with sickle cell defects a year. Across Africa, sickle cell deficiency is known to be a significant inherited disease, with a prevalence of up to 45% across Uganda, for example. The occurrence is also observed in Nigeria, Cameroon, Ghana, Gabon and the Republic of Congo between 20 and 30 percent. There are so many research kits used for sickle cell monitoring including BIOMEDOMICS INC. Sickle SCAN, Streck Laboratories Performance Screening Kit, etc. The NHLBI (National Heart, Lung, and Blood Institute) is the third largest Laboratory of the NIH (National Institutes of Health) and is primarily engaged in the prevention and diagnosis of sickle cell disorders. Some groups are still involved in sickle cell research and diagnostics in the U.S. Sickle cell research is a form of clinical blood test to measure the existence of hemoglobin S, such as the Sickle Cell Disease Association of America (SCDAA). The prices of sickle cell treatment are relatively manageable, and the price range ranges from $2 to $30. Such methods are also used for sickle cell monitoring such as HPC, hemoglobin electrophoresis, or DNA experiments to figure out whether irregular hemoglobin is in the blood of a human. Nevertheless, it is highly necessary to take sickle cell screening before or after birth to reduce the possibility of sickle cell genetic disorders.

Many policy programs to promote the treatment of sickle cell anemia are projected to fuel the increase in sales on the global market for detecting & screening sickle cell anemia.

The success of pilot newborn research projects around countries with sickle cell anemia (Kenya, Congo, Ghana, etc.) drives each government to implement more measures that are expected to fuel the sales growth of this global market in the coming years.

The creation of portable, non-invasive imaging devices for the identification of sickle cell disease seeks to address barriers to the diagnosis and treatment of sickle cell anemia. Market players focus on developing point-of -care testing by means of cost-effective, compact, highly responsive methods such as densitometry, lateral flow immunoassay, micro-fluidic electrophoresis, etc.

Segment Analysis by Region

North America retained highest market share in 2020 and is expected to dominate the world's target market. Newborn screening services are implemented in 50 states in the United States and 8 provinces in Canada that has created an atmosphere conducive to businesses involved in the industry. Neonatal screening services have been well developed in developing regions such as Africa and Asia for the development and introduction of sickle cell disease. In areas where the disease's prevalence rate is 0.05% or higher, Sickle cell screening is generally recommended. Such screening systems provide a routine or tailored check for all newborns with hemoglobin C or sickle cell characteristics. At present, only few countries have adopted newborn screening program, owing to the shortage of appropriate infrastructure for the introduction of newborn screening programs. Recently, increasing awareness and acceptance of sickle cell screening aimed at newborns have been seen in Asia-Pacific countries, especially India. However, these developed countries are implementing approaches to tackle prenatal screening issues in high-income nations, and to streamline follow-up monitoring or diagnosis. It would offer the Asia Pacific industry a big boost in the near future.

COVID-19 Impact

Pandemic situation across the globe has disrupted the business flow worldwide. In 2020 every industry vertical in its 2nd, 3rd, 4th quarter has witnessed substantial drop on production and revenue, this was majorly due to lockdown. The restriction on the operations is impacting the production side and also impacting the supply chain of products. The disrupted supply of raw materials and low operational factories efficiency has contributed in the slower growth of the global market. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process at high operational efficiency, better supply chain models, and effective distribution network. These factors to some extent will help the industry vertical to flourish and aid market growth.

Competitive Landscape

The global market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

The global sickle cell anemia testing & screening market is segmented into technology, age group, and sector. The age group segment is bifurcated into Adult Screening (25 to 60 years), Newborn Screening (12 months and below), and Other Age Groups (1 to 25 & above 60 years). Among age group the Other Age Groups (1 to 25 & above 60 years) segment is expected to account for noticeable revenue share in the global market. The players profiled in the report Quest Diagnostics, BioMedomics Inc., STRECK, Silver Lake Research Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., HEMEX HEALTH, Bio-Rad Laboratories, and Others. 

Market Segmentation

Sickle Cell Anemia Testing & Screening Market By Technology

High-performance Liquid Chromatography
Hemoglobin Electrophoresis
Isoelectric focusing
Paper-Based Rapid Diagnostics
Lateral Flow Immunoassay
Point-of-Care Tests
Others

Sickle Cell Anemia Testing & Screening Market By Age

Adult Screening (25 to 60 years)
Newborn Screening (12 months and below)
Other Age Groups (1 to 25 & above 60 years)

Sickle Cell Anemia Testing & Screening Market By Sector

Private Labs
Government Labs
Corporate Labs
PPP

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa


Frequently Asked Questions

The Sickle Cell Anemia Testing & Screening market value is anticipated to be worth around US$ 550 Mn in 2027.

The Sickle Cell Anemia Testing & Screening market is anticipated to grow around 6% CAGR amid the forecast period 2020-2027.

Asia Pacific is projected to be the fastest growing region in the global market.

Quest Diagnostics, BioMedomics Inc., STRECK, Silver Lake Research Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., HEMEX HEALTH, Bio-Rad Laboratories, and Others are the prominent players in the Sickle Cell Anemia Testing & Screening market.

The report provides insights on global Sickle Cell Anemia Testing & Screening market segment by technology, age, sector and major geographic regions.

The success of pilot newborn research projects around countries with sickle cell anemia (Kenya, Congo, Ghana, etc.) drives each government to implement more measures that are expected to fuel the sales growth of this global market in the coming years.

Cart Summary


60